
    
      This multicenter study is open and consists of a primary and a booster phase. The study has 2
      treatment groups with NeisVac-C™ + Infanrix™ hexa as active controls. In the primary phase,
      one blood sample will be collected from all subjects for immunogenicity analyses- one month
      after the second vaccination dose. In the booster phase, two blood samples will be collected:
      prior to and one month post booster vaccination.
    
  